MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil

Mol Biol Rep. 2022 Jun;49(6):5165-5178. doi: 10.1007/s11033-022-07227-1. Epub 2022 Feb 25.

Abstract

Colorectal cancer is globally one of the most common cancers in all age groups. The current chemotherapy combinations for colorectal cancer treatment include 5-fluorouracil-based regimens; however, drug resistance remains one of the main reasons for chemotherapy failure and disease recurrence. Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression. Several microRNAs affect drug resistance by regulating the drug resistance-related target genes in colorectal cancer. These drug resistance-related miRNAs may be used as promising biomarkers for predicting drug response or as potential therapeutic targets for treating patients with colorectal cancer. This work reviews and discuss the role of selected microRNAs in 5-fluorouracil resistance and their molecular mechanisms in colorectal cancer.

Keywords: 5-fluorouracil; Colorectal cancer; Drug resistance; MicroRNA.

Publication types

  • Review

MeSH terms

  • Cell Line, Tumor
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / metabolism
  • Drug Resistance, Neoplasm / genetics
  • Fluorouracil / pharmacology
  • Fluorouracil / therapeutic use
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs* / metabolism
  • Neoplasm Recurrence, Local / genetics

Substances

  • MicroRNAs
  • Fluorouracil